Skip to search formSkip to main contentSkip to account menu

buflomedil

Known as: 2,4,6-trimethoxyphenyl-3-pyrrolidine propyl ketone, blufomedil, 4-(1-pyrrolidinyl)-1-(2,4,6-trimethoxyphenyl)-1-butanone 
National Institutes of Health

Related topics

Related topics

7 relations

Narrower (5)

Buflomedil LindoFonzylaneLoftylbuflomedil hydrochloride

Broader (2)

PyrrolidinesVasodilator Agents

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2011
Highly Cited
2011
Lactate is an ideal non-invasive marker for evaluating temporal alterations in cell stress and toxicity in repeat dose testing regimes.
Review
2008
Review
2008
Buflomedil for intermittent claudication.
BACKGROUND Intermittent claudication (IC) is pain caused by chronic occlusive arterial disease, that develops in a limb during… 
Highly Cited
2007
Highly Cited
2007
Long-Term Follow-Up of Hypothenar Hammer Syndrome: A Series of 47 Patients
Hypothenar hammer syndrome (HHS) is an uncommon form of secondary Raynaud phenomenon, occurring mainly in subjects who use the… 
Highly Cited
2005
Highly Cited
2005
Continuous Peripheral Nerve Blocks at Home for Treatment of Recurrent Complex Regional Pain Syndrome I in Children
Background:Recurrent complex regional pain syndrome I is not rare in the pediatric population. The authors conducted this study… 
Highly Cited
2001
Highly Cited
2001
Translocation of drug particles in HPMC matrix gel layer: effect of drug solubility and influence on release rate.
Highly Cited
1995
Highly Cited
1995
Drug diffusion front movement is important in drug release control from swellable matrix tablets.
Swellable controlled release devices of buflomedil pyridoxalphosphate in hydroxypropyl methylcellulose were prepared, and their… 
1991
1991
Increase in Skin‐Flap Survival by the Vasoactive Drug Buflomedil
The effect of buflomedil to protect skin tissue from ischemia and necrosis was studied in random cutaneous flaps. Measurements… 
1984
1984
Buflomedil in Arterial Occlusive Disease: Results of a Controlled Multicenter Study
In a double-blind, randomised multicentre study buflomedil, a vasoactive substance, was compared with placebo in the treatment of… 
Review
1981
Review
1981
An Experimental Overview of a New Vasoactive Drug: Buflomedil HCl
A brief review of the pharmacology, pharmacokinetics, and metabolism of buf lomedil-HCl is presented providing a phar macologic… 
1981
1981
Effects of Buflomedil on Erythrocyte Deformability
This brief communication outlines re cent experiments on the effects of buflo medil, a new vasoactive agent, on red cell… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)